Does Cancer Type Influence the Impact of Recurrence? A Review of the Experience of Patients With Breast or Prostate Cancer Recurrence

por Stewart, Ross James, Humphris, Gerald Michael, Donaldson, Jayne, Cruickshank, Susanne
Publicado 2021

Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma

por Hooijkaas, Anna, Gadiot, Jules, Morrow, Michelle, Stewart, Ross, Schumacher, Ton, Blank, Christian U.
Publicado 2012

Immune mediated therapy and MEK inhibition: preclinical assessment of immunobiology and combination activity in vitro and in vivo

por Stewart, Ross, Poon, Edmund, Mullins, Stefanie, Watkins, Amanda, Smith, Paul D, Wilkinson, Robert W
Publicado 2014

A mouse GITRl fusion protein drives T cell activation and antitumor activity in preclinical mouse models of cancer

por Leyland, Rebecca, Watkins, Amanda, Bamber, Lisa, Tigue, Natalie, Young, Lesley, Morrow, Michelle, Hammond, Scott, Wilkinson, Robert, Stewart, Ross
Publicado 2015

A template-free, more environmentally friendly approach for glass micro-texturing

por Jin, Yuhui, Li, Aize, Stewart, Ross J., Hancock, Robert R., Baker, David E., Yongsunthon, Ruchirej, Hughes, Kelleen K., Weidman, David L.
Publicado 2022

Gender specific patterns of age-related decline in aortic stiffness: a cardiovascular magnetic resonance study including normal ranges

por Nethononda, Richard M, Lewandowski, Adam J, Stewart, Ross, Kylinterias, Ilias, Whitworth, Polly, Francis, Jane, Leeson, Paul, Watkins, Hugh, Neubauer, Stefan, Rider, Oliver J
Publicado 2015

Immune combinational therapy targeting OX40 and IDO synergistically enhances efficacy of a cancer vaccine

por Berrong, Zuzana, Ahmad, Shamim, Abu Eid, Rasha, El Andaloussi, Abdeljabar, Sen, Tanusree, Stewart, Ross, Hammond, Scott A, Shrimali, Rajeev, Mkrtichyan, Mikayel, Khleif, Samir N
Publicado 2014

Computational approaches for investigating interfacial adhesion phenomena of polyimide on silica glass

por Min, Kyoungmin, Rammohan, Aravind R., Lee, Hyo Sug, Shin, Jaikwang, Lee, Sung Hoon, Goyal, Sushmit, Park, Hyunhang, Mauro, John C., Stewart, Ross, Botu, Venkatesh, Kim, Hyunbin, Cho, Eunseog
Publicado 2017

The anti-tumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade

por Dovedi, Simon, Adlard, Amy, Lipowska-Bhalla, Grazyna, McKenna, Conor, Jones, Sherrie, Cheadle, Eleanor, Stratford, Ian, Poon, Edmund, Morrow, Michelle, Stewart, Ross, Jones, Hazel, Wilkinson, Robert W, Honeychurch, Jamie, Illidge, Tim
Publicado 2014

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)

por Rosenberg, Jonathan E., Park, Se Hoon, Kozlov, Vadim, Dao, Tu V., Castellano, Daniel, Li, Jian-Ri, Mukherjee, Som D., Howells, Kathryn, Dry, Hannah, Lanasa, Mark C., Stewart, Ross, Bajorin, Dean F.
Publicado 2023

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

por Poon, Edmund, Mullins, Stefanie, Watkins, Amanda, Williams, Geoffrey S., Koopmann, Jens-Oliver, Di Genova, Gianfranco, Cumberbatch, Marie, Veldman-Jones, Margaret, Grosskurth, Shaun E., Sah, Vasu, Schuller, Alwin, Reimer, Corrine, Dovedi, Simon J., Smith, Paul D., Stewart, Ross, Wilkinson, Robert W.
Publicado 2017

Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer

por Schofield, Darren J., Percival-Alwyn, Jennifer, Rytelewski, Mateusz, Hood, John, Rothstein, Raymond, Wetzel, Leslie, McGlinchey, Kelly, Adjei, Grace, Watkins, Amanda, Machiesky, LeeAnn, Chen, Weimin, Andrews, John, Groves, Maria, Morrow, Michelle, Stewart, Ross A., Leinster, Andrew, Wilkinson, Robert W., Hammond, Scott A., Luheshi, Nadia, Dobson, Claire, Oberst, Michael
Publicado 2021

Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial

por Yap, Timothy A., Bardia, Aditya, Dvorkin, Michael, Galsky, Matthew D., Beck, J. Thaddeus, Wise, David R., Karyakin, Oleg, Rubovszky, Gábor, Kislov, Nikolay, Rohrberg, Kristoffer, Joy, Anil Abraham, Telli, Melinda L., Schram, Alison M., Conte, Umberto, Chappey, Colombe, Stewart, Ross, Stypinski, Daria, Michelon, Elisabete, Cesari, Rossano, Konstantinopoulos, Panagiotis A.
Publicado 2022

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

por Wildsmith, Sophie, Li, Weimin, Wu, Song, Stewart, Ross, Morsli, Nassim, Raja, Rajiv, Zhang, Qu, Ye, Jiabu, He, Philip, Shetty, Jagdish, Yovine, Alejandro, Holoweckyj, Nicholas, Real, Katia, Walker, Jill, Wrona, Magdalena, de los Reyes, Melissa, Barker, Craig, Whiteley, Jessica, Haddad, Robert, Licitra, Lisa, Ferris, Robert, Fayette, Jérôme, Zandberg, Dan P., Siu, Lillian L., Mesía, Ricard
Publicado 2023

Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy

por Williams, Geoffrey S., Mistry, Bina, Guillard, Sandrine, Ulrichsen, Jane Coates, Sandercock, Alan M., Wang, Jun, González-Muñoz, Andrea, Parmentier, Julie, Black, Chelsea, Soden, Jo, Freeth, Jim, Jovanović, Jelena, Leyland, Rebecca, Al-Lamki, Rafia S., Leishman, Andrew J., Rust, Steven J., Stewart, Ross, Jermutus, Lutz, Bradley, John R., Bedian, Vahe, Valge-Archer, Viia, Minter, Ralph, Wilkinson, Robert W.
Publicado 2016

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial

por Schram, Alison M., Colombo, Nicoletta, Arrowsmith, Edward, Narayan, Vivek, Yonemori, Kan, Scambia, Giovanni, Zelnak, Amelia, Bauer, Todd M., Jin, Ning, Ulahannan, Susanna V., Colleoni, Marco, Aftimos, Philippe, Donoghue, Mark T. A., Rosen, Ezra, Rudneva, Vasilisa A., Telli, Melinda L., Domchek, Susan M., Galsky, Matthew D., Hoyle, Margaret, Chappey, Colombe, Stewart, Ross, Blake-Haskins, John A., Yap, Timothy A.
Publicado 2022

MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential

por Tigue, Natalie J., Bamber, Lisa, Andrews, John, Ireland, Samantha, Hair, James, Carter, Edward, Sridharan, Sudharsan, Jovanović, Jelena, Rees, D. Gareth, Springall, Jeremy S., Solier, Emilie, Li, Yi-Ming, Chodorge, Matthieu, Perez-Martinez, David, Higazi, Daniel R., Oberst, Michael, Kennedy, Maureen, Black, Chelsea M., Yan, Li, Schwickart, Martin, Maguire, Shaun, Cann, Jennifer A., de Haan, Lolke, Young, Lesley L., Vaughan, Tristan, Wilkinson, Robert W., Stewart, Ross
Publicado 2017